Why the study?
Does complex-binding of anthracyclines to DNA reduce cardiotoxicity in patients with acute myeloblastic leukemia?
Population
3 patients with acute myeloblastic leukemia
Comparison
Daunorubicin-DNA complex vs Free form daunorubicin
Design
Case_series
Authors
Loading...
May permit higher cumulative anthracycline doses in AML without cardiotoxicity; leaves open confirmation in prospective trials.
Does complex-binding of anthracyclines to DNA reduce cardiotoxicity in patients with acute myeloblastic leukemia?
Complex-binding of anthracyclines to DNA may reduce clinical cardiotoxicity, allowing for higher cumulative doses in leukemia patients.
Paul et al. (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: